INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 44h ago
HOUSE PTR4h ago
SEC 13F4h ago
ROBINHOOD CHAIN4h ago
SEC FORM 4/Grant or awardVerified data

Kreitzer Anatol reported MPLT

Chief Discovery Officer · MapLight Therapeutics, Inc. · Voting Common Stock

Side
A
Value
—
Shares
6,020
Price
—
Executed
Feb 5, 2026
Disclosed
Feb 9, 2026
Disclosure timeline4 days from execution to publication · legal deadline 2 business days
Feb 5 executedFeb 9, 2026 disclosed

MPLT · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
9/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+1 / 25

No reported dollar value · 2.4% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · MPLT

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    32
    FP
    Foff Erin PennockChief Medical Officer
    MPLTMapLight Therapeutics, Inc.
    Open-market sale
    		SELL$124K
    15.4K sh
    		Oct 15, 2026Oct 16, 2026
    traded Oct 15, 2026
    		+1dSEC FORM 4

    Evidence

    39
    KA
    Kreitzer AnatolChief Discovery Officer
    MPLTMapLight Therapeutics, Inc.
    Open-market sale
    		SELL$96K
    12.2K sh
    		Oct 15, 2026Oct 16, 2026
    traded Oct 15, 2026
    		+1dSEC FORM 4

    Evidence

    36
    HK
    Hanson KristopherGeneral Counsel
    MPLTMapLight Therapeutics, Inc.
    Open-market sale
    		SELL$73K
    9,020 sh
    		Oct 15, 2026Oct 16, 2026
    traded Oct 15, 2026
    		+1dSEC FORM 4

    Evidence

    43
    LW
    Lillie James WoodruffChief Scientific Officer
    MPLTMapLight Therapeutics, Inc.
    Open-market sale
    		SELL$93K
    11.5K sh
    		Oct 15, 2026Oct 16, 2026
    traded Oct 15, 2026
    		+1dSEC FORM 4

    Evidence

    5
    HK
    Hanson KristopherGeneral Counsel
    MPLTMapLight Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$193K
    16.5K sh
    		Sep 16, 2026Sep 18, 2026
    traded Sep 16, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FP
    Foff Erin PennockChief Medical Officer
    MPLTMapLight Therapeutics, Inc.
    Grant or award
    		A—
    13.4K sh
    		Aug 17, 2026Aug 19, 2026
    traded Aug 17, 2026
    		+2dSEC FORM 4

    Evidence

    5
    KA
    Kreitzer AnatolChief Discovery Officer
    MPLTMapLight Therapeutics, Inc.
    Grant or award
    		A—
    6,020 sh
    		Aug 17, 2026Aug 19, 2026
    traded Aug 17, 2026
    		+2dSEC FORM 4

    Evidence

    5
    KA
    Kreitzer AnatolChief Discovery Officer
    MPLTMapLight Therapeutics, Inc.
    Grant or award
    		A—
    24.5K sh
    		Aug 17, 2026Aug 19, 2026
    traded Aug 17, 2026
    		+2dSEC FORM 4

    Evidence

    2
    FP
    Foff Erin PennockChief Medical Officer
    MPLTMapLight Therapeutics, Inc.
    Grant or award
    		A—
    54.2K sh
    		Aug 17, 2026Aug 19, 2026
    traded Aug 17, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CT
    Cox TroyDirector
    MPLTMapLight Therapeutics, Inc.
    Grant or award
    		A—
    7,864 sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LL
    Luneborg Nanna LiebachDirector
    MPLTMapLight Therapeutics, Inc.
    Grant or award
    		A—
    14.9K sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    LL
    Luneborg Nanna LiebachDirector
    MPLTMapLight Therapeutics, Inc.
    Grant or award
    		A—
    3,932 sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    WC
    Walker Maria CDirector
    MPLTMapLight Therapeutics, Inc.
    Grant or award
    		A—
    14.9K sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    13
    WC
    Walker Maria CDirector
    MPLTMapLight Therapeutics, Inc.
    Grant or award
    		A—
    3,932 sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GJ
    Garnett Timothy JohnDirector
    MPLTMapLight Therapeutics, Inc.
    Grant or award
    		A—
    3,932 sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    9
    CT
    Cox TroyDirector
    MPLTMapLight Therapeutics, Inc.
    Grant or award
    		A—
    29.8K sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    5
    GJ
    Garnett Timothy JohnDirector
    MPLTMapLight Therapeutics, Inc.
    Grant or award
    		A—
    14.9K sh
    		Jun 23, 2026Jun 25, 2026
    traded Jun 23, 2026
    		+2dSEC FORM 4

    Evidence

    16
    HK
    Hanson KristopherGeneral Counsel
    MPLTMapLight Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$210K
    6,979 sh
    		May 11, 2026May 11, 2026
    traded May 11, 2026
    		+0dSEC FORM 4

    Evidence

    13
    HK
    Hanson KristopherGeneral Counsel
    MPLTMapLight Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$7,841
    284 sh
    		May 11, 2026May 11, 2026
    traded May 11, 2026
    		+0dSEC FORM 4

    Evidence

    13
    FP
    Foff Erin PennockChief Medical Officer
    MPLTMapLight Therapeutics, Inc.
    Open-market sale · 10b5-1 plan
    		SELL$3,405
    117 sh
    		May 7, 2026May 11, 2026
    traded May 7, 2026
    		+4dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002021238-26-000004
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Feb 5, 2026
    Published
    Feb 9, 2026
    Ingested by INSIDER
    Nov 5, 04:18 UTC
    Last re-read
    Nov 5, 04:18 UTC

    Extracted facts

    Filer
    Kreitzer Anatol
    Role
    Chief Discovery Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    MapLight Therapeutics, Inc.
    Ticker
    MPLT
    Shares
    6,020
    Price per share
    $0
    Execution date (reported)
    Feb 5, 2026
    Owned after transaction
    259.9K shares
    Days from execution to publication
    4

    What this establishes

    Kreitzer Anatol filed this Form 4 reporting a grant or award of MPLT on Feb 5, 2026. It became public on Feb 9, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Discovery Officer
    Kreitzer Anatolcik:0002021238
    Issuer
    MapLight Therapeutics, Inc.cik:0001770069

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.